After recent research studies have discovered that Multaq can increase a patient’s chance of suffering from severe cardiovascular complications, Health Canada is advising doctors not to prescribe the drug Multaq to patients who have certain heart rhythm disorders.
Multaq, manufactured by Sanofi, is approved in the United States to treat abnormal heart rate and rhythm. However, in Canada, it is only approved to treat patients that have different types of intermittent atrial fibrillation, which is not as permanent condition. The PALLAS study of Multaq was stopped after early data showed that the patients that had permanent atrial fibrillation were more likely to suffer from a heart-related complication or stroke. This was in comparison to patients that were not given Multaq.
The research trial was supposed to explore Multaq’s use in patients that were over the age of 65 that had permanent atrial fibrillation, as well as other forms of heart disease. Health Canada said that the patients taking Multaq shouldn’t stop taking the drug without first discussing with their doctors.
It is also recommended that patients speak to their doctor if they are worried about possible concerns after taking Multaq, or if they start to experience any unexpected or worsening symptoms while taking the drug. Some of the signs to watch out for include increasing shortness of breath, swelling of feet or legs, trouble breathing while lying down or sleeping and/or shortness of breath while moving around. If you suffer from any of the side effects associated with taking Multaq, contact your doctor right away and then you can contact attorney Greg Jones for a free consultation. I am experienced at fighting Multaq lawsuits, and I may be able to help you recover money for your injuries, pain and suffering.
About Greg Jones Law
You May Also Like